Ertan-Ahmed, S. Et Al. 2019. GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.. 2019 ASCO Annual Meeting I .

Ertan-Ahmed, S., Kiehl, M. G., Radinoff, A., Graklanov, V., Tzvetkov, N., Mihăescu, R., ... ÖZATLI, D.(2019). GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma. . 2019 ASCO Annual Meeting I

Ertan-Ahmed, Senem Et Al. "GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.," 2019 ASCO Annual Meeting I, 2019

Ertan-Ahmed, Senem Et Al. "GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.." 2019 ASCO Annual Meeting I , 2019

Ertan-Ahmed, S. Et Al. (2019) . "GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.." 2019 ASCO Annual Meeting I .

@conferencepaper{conferencepaper, author={Senem Ertan-Ahmed Et Al. }, title={GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.}, congress name={2019 ASCO Annual Meeting I}, city={}, country={}, year={2019}}